Story · Medicine & Biotech
Verismo aims to cut CAR-T manufacturing time with Stanford's in vivo technology
1 outlet · first reported by Korea Biomedical Review on
HLB Innovation's U.S. subsidiary Verismo Therapeutics said it has licensed Stanford Medicine's PACK-IT technology, which enables CAR-T cells to be generated directly inside the body, as it seeks to expand its KIR-CAR platform into in vivo cell therapies.The technology, developed by a team led by Cry (Korea Biomedical Review)
Coverage, in order
-
Verismo aims to cut CAR-T manufacturing time with Stanford's in vivo technology
HLB Innovation's U.S. subsidiary Verismo Therapeutics said it has licensed Stanford Medicine's PACK-IT technology, which enables CAR-T cells to be generated directly inside the body, as it seeks to expand its KIR-CAR platform into in vivo cell therapies.The technology, developed by a team led by Cry
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.